After rebounding earlier this year from a lengthy period of underperformance, health care stocks have found themselves lagging again over the past month or so. And that, Validea CEO John Reese says, is helping create some buying opportunities.
“My guru strategies have taken note by taking advantage of relatively lower prices,” Reese writes in a recent RealMoney column. “They have given high grades to a number of health care stocks. … These strategies are automated analyses that mirror the strategies of some of history’s most savvy investors, and they have proven their worth over the eight-plus years I have used them.”
Among the stocks Reese discusses: drug giant AstraZeneca, which gets high marks from his Peter Lynch- and James O’Shaughnessy-based models. To read the full article, click here.